TAGLN2 is a major cause of paclitaxel resistance in BC patients, and new strategies to reverse paclitaxel resistance in BC patients include various drugs and pathways to reduce TAGLN2 expression (Cai et al., 2014; Wang et al., 2019). This evidence concerns the gene TAGLN2 and breast cancer.